Pharmaceutical Compliance Consulting & Quality Management

In the highly regulated pharmaceutical markets of China and the Asia-Pacific region, maintaining regulatory compliance and product integrity is of critical importance to commercial success. Regulatory challenges are complex and continually evolving, and your ability to meet them efficiently can make or break your market access. At Cisema, our company is your trusted partner for pharmaceutical compliance consulting. We assist clients in achieving and maintaining compliance by providing tailored services that ensure your systems meet the highest standards.

Our expertise includes developing and managing comprehensive Quality Management Systems (QMS) for clients, as well as developing processes and systems for ongoing compliance. We align quality assurance processes with business goals, helping organizations across the life sciences industry improve operational efficiency, strengthen regulatory affairs capabilities, and navigate inspections with confidence.

Pharmaceutical Industry Compliance
Regulatory Compliance Consulting for the Pharmaceutical Industry

Our Pharmaceutical Compliance Services in China & Asia Pacific

Clinical Quality Assurance & GCP Compliance

We provide specialized regulatory compliance consulting to ensure your clinical trials meet Good Clinical Practice (GCP) guidelines and regional regulatory requirements. Our dedicated team of compliance consultants and industry experts supports pharmaceutical companies throughout the clinical development lifecycle — from protocol design to data collection and reporting.

Our proactive approach helps identify and resolve potential compliance gaps early, safeguarding patient safety, ensuring data integrity, and reducing risk during inspections. By prioritizing clinical quality assurance, we help you maintain audit-ready trial documentation, accelerate development timelines, and support successful regulatory submissions across China and the Asia-Pacific region.

GxP, QMS & SOP Review

We conduct GxP audits and assess your GxP compliance, Quality Management System (QMS), and Standard Operating Procedures (SOPs) to identify risks before they become issues. Our compliance consulting approach ensures your systems are robust, helping your organization align with local regulatory requirements and prepare for inspections with clear, documented evidence.

Ingredient Compliance Checks

We verify the regulatory status and documentation of your raw materials to ensure full regulatory compliance with NMPA and Asia-Pacific requirements. Our ingredient checks help prevent costly delays, reduce risk and ensure your products are approved for market use without issue.

Vendor Audits & Supply Chain Oversight

We conduct vendor audits that evaluate supply chain compliance, ensuring suppliers meet GMP and quality assurance standards. Our work supports process controls, strengthens audit readiness, and safeguards the regulatory process across your value chain.

Pre-Approval Inspection Readiness

We prepare your facilities and documentation for pre-approval inspections from China’s NMPA and other Asia-Pacific regulatory authorities. From mock audits to onsite support, our team ensures your systems meet all relevant requirements, reducing risks and accelerating approvals.

Factory Audits in China & Abroad

Whether you manufacture in China, elsewhere in Asia, or globally, we conduct GMP audits to evaluate compliance with local and international requirements. Our assessments support continuous improvement, help you avoid warning letters, and reduce non-compliance risks across your operations.

Regulatory Inspection Support

We guide you through the full inspection process with China’s NMPA and Asia-Pacific regulators, from initial preparations to post-inspection remediation efforts. Our local and remote teams ensure your operations are fully aligned and ready for approval.

Why Work with Cisema?

Local expertise with global reach

Our bilingual teams bridge international quality standards with local regulations

Proven track record

Over 20 years supporting market approvals and compliance in China and Asia Pacific

End-to-end solutions

From system setup to post-market surveillance, we ensure quality management and regulatory compliance throughout the product lifecycle

Industry breadth

Cross-sector expertise in life sciences, food, veterinary, consumer and industrial goods

Role of a China Agent

Frequently Asked Questions

It ensures your products meet safety, efficacy, and quality standards throughout development and manufacturing, while ensuring compliance with national and regional regulations across Asia Pacific.

We assess your systems, SOPs, and documentation against local regulatory requirements. Our gap analyses and recommendations strengthen regulatory compliance and improve operational efficiency.

Yes. We conduct ingredient reviews to ensure safety and regulatory alignment with NMPA standards in China and relevant regulations across the Asia-Pacific region.

Vendor audits help prevent compliance risks and ensure consistent product quality. We identify gaps and verify supplier adherence to regulatory expectations in China and Asia Pacific.

We help you respond with effective corrective and preventive actions (CAPA), support remediation, and guide you through reinspection — minimizing regulatory impact in China and across the region.

We recommend annual internal audits and pre-inspection assessments. Our third-party audits help keep your systems compliant and inspection-ready across all Asia-Pacific jurisdictions.

Absolutely. We specialize in supporting global pharmaceutical companies entering or expanding in China and the Asia-Pacific region, bridging global GxP standards with local regulatory affairs requirements.

Request a Proposal from Our Pharma Team

Let Cisema help turn your plans into reality.

Request Proposal

Explore Related Services

Pharmaceutical Development & Strategy

Drive successful market entry and growth with confidence. Our pharmaceutical regulatory consulting experts support biotech and life sciences companies in streamlining drug development, accelerating approvals, and achieving commercialization through tailored strategies, clinical insights, and end-to-end compliance solutions.

Learn more

Health Economics & Market Access

Accelerate access across China and Asia Pacific with confidence. Our market access consulting experts help life sciences companies optimize patient access, navigate pricing and reimbursement challenges, and enable commercial success through real world evidence, health economics, and tailored access strategies.

Learn more

Pharmacovigilance

Ensure drug safety and regulatory compliance across China and Asia Pacific with confidence. Our pharmacovigilance consulting experts support life sciences companies in managing risks, meeting evolving safety requirements, and maintaining market authorization through end-to-end PV solutions tailored to local regulations.

Learn more

Pharmaceutical Regulatory Affairs

Navigate regulatory complexity across China and Asia Pacific with confidence. Our regulatory affairs consulting experts support life sciences companies with strategic planning, compliant submissions, and local representation to accelerate approvals and ensure market readiness.

Learn more

Read the Latest Regulatory News

View More

Indonesia Mandates Pre-Shipment Halal Verification for Imported Products

BPJPH Regulation No. 4 of 2026 introduces pre-shipment halal verification and LPPH reports for imported goods starting September 2026.

September 25, 2026
Indonesia Mandates Pre-Shipment Halal Verification for Imported Products

TFDA Updates Processing Time Limits for Public Applications in Taiwan

Taiwan's TFDA has revised its processing time limits table for public applications, adding eight application items and amending two existing items.

September 9, 2026
TFDA Updates Processing Time Limits for Public Applications in Taiwan

China Proposes ICH E6(R3) Annex 2 Compliance for Clinical Trials from 2027

China proposes ICH E6(R3) Annex 2 implementation from January 2027, with public comments open for one month from August 10 2026.

August 31, 2026
China Proposes ICH E6(R3) Annex 2 Compliance for Clinical Trials from 2027

Guangdong MPA Implements 2026 Guideline for Importing Hong Kong and Macao Drugs into the Greater Bay Area

The guideline introduces more detailed evidence requirements for Hong Kong and Macao drug imports while retaining a streamlined pathway for products already approved under the GBA Connect scheme.

August 31, 2026
Guangdong MPA Implements 2026 Guideline for Importing Hong Kong and Macao Drugs into the Greater Bay Area

CDE Proposes Revised Standards for Written Supplementary Information Requests

The draft clarifies when CDE may issue written supplementary information requests and when major deficiencies identified during review may instead lead to a non-approval conclusion.

August 24, 2026
CDE Proposes Revised Standards for Written Supplementary Information Requests

Beijing Establishes Ongoing Whitelist Scheme for Biopharmaceutical R&D Material Imports

The R&D import whitelist scheme streamlines customs clearance while maintaining specific eligibility, traceability, and risk-control requirements.

August 24, 2026
Beijing Establishes Ongoing Whitelist Scheme for Biopharmaceutical R&D Material Imports
Previous
Previous

Get in Touch with Our Pharma Consultants

Speak with our pharma consultants to explore how our quality assurance and compliance consultants can help your organization navigate the region's complex pharmaceutical markets.

Request Proposal